Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ANNOUNCES FILING OF PRELIMINARY BASE SHELF PROSPECTUS

Onco-Innovations Ltd. has filed a preliminary base shelf prospectus dated Feb. 3, 2026, with the securities regulatory authorities in each of the provinces of Alberta, British Columbia, Manitoba and Ontario. The base shelf prospectus has been filed, but is not yet final, and the securities described therein may not be sold until: (i) a receipt for a final short form base shelf prospectus is obtained from the applicable securities regulatory authorities; and (ii) a prospectus supplement containing a description of any particular securities offering is filed with the applicable securities regulatory authorities.

The base shelf prospectus, once final and a receipt is obtained, is intended to allow the company to offer and issue, from time to time, common shares, debt securities, warrants, subscription receipts and units (or any combination thereof) during the 25-month period that a final base shelf prospectus remains effective. The specific terms of any future offering (including, where applicable, the number and price of the securities offered and the use of proceeds) will be set out in one or more prospectus supplements filed in connection with any such offering. The company has filed the base shelf prospectus to maintain financial flexibility, and there is no certainty that any securities will be offered or sold under the base shelf prospectus within its effective period.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.